Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Researchers have developed and are testing a small, implanted gastric balloon that people can inflate or deflate to feel full ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

If you're in a relationship that faces struggles with weight and are considering GLP-1 medications like Ozempic, consider ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel fuller ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

B&D Nutritional Ingredients, Inc., a raw material distributor in the dietary supplement industry and exclusive U.S. distribution partner to CarnoSyn ® Brands and Natural Alternatives International, ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...